Your immune system and cancer - Jonathan Cebon - BreaCan 5 August 2015
•
1 like•1,287 views
Professor Cebon discusses the link between the immune system and cancer, immunotherapy and the current research being undertaken to develop new treatments that target cancer cells. This session was jointly hosted by BreaCan and Olivia Newton-John Cancer and Wellness Centre.
Report
Share
Report
Share
Recommended
Tumor immunity
The immune system plays an important role in tumor immunity by recognizing and destroying tumor cells. However, tumors have developed several mechanisms to evade the immune system. Tumors express a variety of tumor antigens that can elicit an immune response, but they often downregulate antigen expression or lose antigenicity over time. Additionally, tumors employ immunosuppressive strategies like increasing immunosuppressive cytokines or reducing co-stimulatory molecules to avoid immune detection and destruction. While immune surveillance exists, tumors have found ways to circumvent it through immune escape mechanisms.
Cancer immunology
This document provides definitions and explanations of key cancer-related terms:
- Cancer is characterized by uncontrolled cell growth and spread. Benign tumors are not invasive while malignant tumors continue growing and spreading. Metastasis occurs when cancer cells spread from the original tumor to other parts of the body.
- Carcinomas arise from epithelial tissues, sarcomas from connective tissues, and leukemia from blood-forming tissues in the bone marrow. Carcinogens are agents that can cause cancer. Tumor antigens include those from mutated genes and overexpressed proteins. Immunotherapy harnesses the immune system to fight cancer using approaches like monoclonal antibody treatment, adoptive cell transfer, and cancer vaccines.
Tumor Immunity
This presentation deals with the concept of Tumor immunity. It cover different types of Tumor and tumor antigens. How immunology plays role in tumor detection and diagnosis is also explained in this presentation. Concept of Tumor imunoprophylaxis and tumor immunotherapy is also explained.
Tumor immunity
1. The document discusses tumor immunity and classification of tumor antigens. It describes the adaptive and innate immune system including lymphocytes like T cells, B cells, NK cells, and antigen presenting cells.
2. Tumor antigens are classified based on their expression patterns and molecular structure. They include tumor specific antigens from viruses, overexpressed cellular proteins, products of mutated oncogenes, oncofetal antigens, and antigens from altered glycoproteins.
3. The immune response to tumors involves cellular immunity from CTLs and NK cells and humoral immunity from antibodies. However, tumor cells can evade the immune system by lacking costimulatory signals and decreasing MHC I expression. Immunotherapy and vaccines aim to enhance tumor
Iimmunity to tumors
1. Cancer is caused by uncontrolled cell growth that can spread and kill the host. Tumors can be benign or malignant.
2. The immune system plays an important role in tumor rejection through spontaneous regression, lymphocyte infiltration of tumors, and increased cancer risk with immunosuppression.
3. Tumors elicit specific adaptive immune responses through antigens, but the immune system often fails to prevent tumor growth due to weak immunogenicity, rapid tumor growth, and immune evasion mechanisms.
Tumour immunology leture notes
This document provides an overview of tumor immunology, including definitions of cancer and carcinogenesis, tumor antigens, the immune response to cancer, and mechanisms by which tumors escape the immune system. It discusses how tumors stimulate an immune response through antigens but also ways they can evade immunity, such as through low immunogenicity, antigen modulation, and immune suppression. It describes experimental evidence for tumor antigens and the immune response against tumors.
Immunology and cancer
Cytokine-tumor interactions within its microenvironment play a critical role in pathogenesis and management of any neoplasm. Here, I summarize points from a 2004 Nature paper that are still pertinent today.
Slide Template: www.presentationmagazine.com
Cancer Immuno editing
1) T cell responses against antigens expressed in autochthonous lung tumors can delay malignant tumor progression. However, these T cell responses are not sustained over time.
2) Vaccination against antigens expressed in autochthonous lung tumors promotes an initial protective T cell response but also drives tumor antigen loss, allowing tumor escape.
3) Transplantation of lung tumor cell lines or vaccination against antigens in transplantable lung tumor models results in rejection of tumor or selection of antigen-loss variants, demonstrating immune editing.
Recommended
Tumor immunity
The immune system plays an important role in tumor immunity by recognizing and destroying tumor cells. However, tumors have developed several mechanisms to evade the immune system. Tumors express a variety of tumor antigens that can elicit an immune response, but they often downregulate antigen expression or lose antigenicity over time. Additionally, tumors employ immunosuppressive strategies like increasing immunosuppressive cytokines or reducing co-stimulatory molecules to avoid immune detection and destruction. While immune surveillance exists, tumors have found ways to circumvent it through immune escape mechanisms.
Cancer immunology
This document provides definitions and explanations of key cancer-related terms:
- Cancer is characterized by uncontrolled cell growth and spread. Benign tumors are not invasive while malignant tumors continue growing and spreading. Metastasis occurs when cancer cells spread from the original tumor to other parts of the body.
- Carcinomas arise from epithelial tissues, sarcomas from connective tissues, and leukemia from blood-forming tissues in the bone marrow. Carcinogens are agents that can cause cancer. Tumor antigens include those from mutated genes and overexpressed proteins. Immunotherapy harnesses the immune system to fight cancer using approaches like monoclonal antibody treatment, adoptive cell transfer, and cancer vaccines.
Tumor Immunity
This presentation deals with the concept of Tumor immunity. It cover different types of Tumor and tumor antigens. How immunology plays role in tumor detection and diagnosis is also explained in this presentation. Concept of Tumor imunoprophylaxis and tumor immunotherapy is also explained.
Tumor immunity
1. The document discusses tumor immunity and classification of tumor antigens. It describes the adaptive and innate immune system including lymphocytes like T cells, B cells, NK cells, and antigen presenting cells.
2. Tumor antigens are classified based on their expression patterns and molecular structure. They include tumor specific antigens from viruses, overexpressed cellular proteins, products of mutated oncogenes, oncofetal antigens, and antigens from altered glycoproteins.
3. The immune response to tumors involves cellular immunity from CTLs and NK cells and humoral immunity from antibodies. However, tumor cells can evade the immune system by lacking costimulatory signals and decreasing MHC I expression. Immunotherapy and vaccines aim to enhance tumor
Iimmunity to tumors
1. Cancer is caused by uncontrolled cell growth that can spread and kill the host. Tumors can be benign or malignant.
2. The immune system plays an important role in tumor rejection through spontaneous regression, lymphocyte infiltration of tumors, and increased cancer risk with immunosuppression.
3. Tumors elicit specific adaptive immune responses through antigens, but the immune system often fails to prevent tumor growth due to weak immunogenicity, rapid tumor growth, and immune evasion mechanisms.
Tumour immunology leture notes
This document provides an overview of tumor immunology, including definitions of cancer and carcinogenesis, tumor antigens, the immune response to cancer, and mechanisms by which tumors escape the immune system. It discusses how tumors stimulate an immune response through antigens but also ways they can evade immunity, such as through low immunogenicity, antigen modulation, and immune suppression. It describes experimental evidence for tumor antigens and the immune response against tumors.
Immunology and cancer
Cytokine-tumor interactions within its microenvironment play a critical role in pathogenesis and management of any neoplasm. Here, I summarize points from a 2004 Nature paper that are still pertinent today.
Slide Template: www.presentationmagazine.com
Cancer Immuno editing
1) T cell responses against antigens expressed in autochthonous lung tumors can delay malignant tumor progression. However, these T cell responses are not sustained over time.
2) Vaccination against antigens expressed in autochthonous lung tumors promotes an initial protective T cell response but also drives tumor antigen loss, allowing tumor escape.
3) Transplantation of lung tumor cell lines or vaccination against antigens in transplantable lung tumor models results in rejection of tumor or selection of antigen-loss variants, demonstrating immune editing.
Tumor immunology by nidhi
What is immunology?
What is Tumor?
Types of tumor
Classification of Malignant tumors
Malignant transformation of cells
General features of Tumor immunity
Tumor antigens
Tumor specific antigen
Tumor associated antigens
Immune response to tumor
Evasion of immune response by tumor
Cancer Immunosurveillance versus Immunoediting
Immunotechniques
RIA
ELISA
ppt 1
The document discusses tumor immunology and tumor markers. It provides information on:
1) How tumors form from normal cells through mutations, carcinogens or viruses and become antigenically different. The immune system normally recognizes and destroys these cells.
2) Mechanisms by which tumors can escape immune detection including loss of antigen presentation or production of immunosuppressive factors.
3) How the immune system acts as a surveillance system to detect and eliminate neoplastic cells through natural killer cells, cytotoxic T-cells, antibodies and complement activation.
4) Tumor markers that can be used for diagnosis and monitoring treatment including tumor antigens like alpha-fetoprotein and carcinoembryonic antigen, and tumor
Tumour immunology
The document discusses tumors and cancer. It defines tumors as abnormal tissue growth resulting from mutations in DNA that alter cell growth regulation. There are two types: benign tumors, which are non-cancerous and have defined boundaries; and malignant tumors (cancers), which invade other tissues and spread via the bloodstream and lymphatic system. Cancers arise from mutations in oncogenes and tumor suppressor genes, which normally regulate cell division. Environmental factors like radiation, viruses, hormones, and chemicals can also increase cancer risk by further mutating these genes. The body has some defense mechanisms to prevent cancer development, like shedding mutated cells, but cancers can still form when too many mutations accumulate.
Cancer and the Immune System
The presentation outlines aspects of immunity against cancer, evasion strategies by cells, immunotherapy in cancer, cancer vaccines etc. Download and view the slideshow for better experience.
Prepared in Sept 2014
Immune response against tumors
The document discusses various types of tumor antigens recognized by T cells and immune mechanisms of tumor rejection. It covers tumor-associated antigens and tumor-specific antigens, and describes four main categories of tumor antigens: 1) abnormally expressed but unmutated cellular proteins, 2) products of mutated self genes, 3) oncogenes and mutated tumor suppressor genes, and 4) antigens of oncogenic viruses. It also discusses how tumors can evade immune responses through mechanisms like antigen loss, inhibiting immune molecules, regulatory T cells, and secreting immunosuppressive factors. Novel immunotherapies discussed include therapeutic cancer vaccines, monoclonal antibodies, immune checkpoint inhibitors, adoptive cell therapies, and oncolytic viruses.
Cancer immunology
The document summarizes key concepts in cancer immunology. It defines cancer and how the immune system views cancer cells. It describes how the innate and adaptive immune systems recognize and attack tumors through mechanisms like complement activation, NK cell activation, and T cell responses. It also discusses how cancers can evade the immune system through antigen loss, immunosuppressive microenvironments, and immune checkpoint proteins. The document concludes by outlining several immunotherapy approaches like non-specific immune stimulation, T cell therapy, immune checkpoint inhibitors, cancer vaccines, and monoclonal antibodies.
Cancer and immune system
Cancer can both weaken the immune system and be fought by the immune system. It can weaken immunity by spreading to bone marrow and reducing blood cell production, or through side effects of treatments like chemotherapy and radiation. However, parts of the immune system also recognize cancer cells as abnormal and try to kill them. New immunotherapies aim to boost this response by using antibodies, cytokines, vaccines, and other methods to help the immune system better eliminate cancer cells. A balanced relationship exists between cancer and immunity.
CANCER IMMUNOLOGY- TERMINOLOGIES
Cancer immunology involves the immune system's response to tumors. There are several key terms: tumors can be benign (non-invasive) or malignant (invasive and metastatic). Malignant tumors are called cancers. Cancers arise from epithelial tissues, blood cells, or connective tissues. Chemicals, radiation, viruses and genetic mutations can cause malignant transformation of cells. Oncogenes promote tumor growth while tumor suppressors inhibit growth. Tumors express antigens that can be recognized by the immune system, including tumor-specific antigens from mutations and tumor-associated antigens that are normally expressed elsewhere.
Tumourclasss
1. A tumor is abnormal tissue consisting of genetic-altered cells that can arise due to mutations or environmental factors like radiation or infections.
2. The immune system can recognize and destroy early cancer cells but tumors evolve mechanisms to evade the immune response through loss of antigen presentation or secretion of factors that suppress T cells.
3. Immunotherapy aims to enhance anti-tumor immunity through vaccines, adoptive cell therapies, monoclonal antibodies, or cytokines to help the immune system overcome tumor evasion and eliminate cancer cells in a targeted manner with less toxicity than other treatments.
Tumor Immunology presentation by Sharmista
Tumor, Tumor immunology, cancer, hallmarks of cancer, carcinoma, lymphoma, metastasis, malignant, benign, angiogenesis, oncogenes and cancer induction, kuby detailed study quick revision, proto-oncogenes, tumor antigens, antibody, experiments for tumor antigens, methods for characterization of TSTA, Immunoediting, Current research n new approaches, monoclonal antibody
Cancer immunology
Tumor immunotherapy activates a patient's immune system to fight cancer. There are two main types of immunotherapy - antigen-specific therapies which directly transfer immune cells or induce immune responses to specific antigens, and non-specific therapies which stimulate immune function regardless of antigen specificity. Adoptive transfer directly transfers immune cells while vaccination administers antigens to induce immune responses. Non-specific therapies were once tested on their own but are now used alongside antigen-specific therapies to enhance communication between immune cells.
Theory of Immune surveillance
The document discusses the theory of immune surveillance, which proposes that the immune system patrols the body to recognize and destroy both invading pathogens and abnormal host cells, such as cancer cells. It provides evidence from experiments in mice and clinical observations in humans that support this theory. The key components of immune surveillance systems that eliminate cancer cells are natural killer cells, cytotoxic T-lymphocytes, B-cells, and their mechanisms of action. The process by which cancer cells can evade immune destruction is called immunoediting, which occurs through three sequential phases - elimination, equilibrium, and escape.
Cancer immunology
This document provides an overview of cancer immunology, including how tumors evade and enhance immune responses. It discusses the roles of various immune cells like NK cells, macrophages, and cytotoxic T lymphocytes in targeting tumor antigens. The document also covers cancer immunotherapy approaches like manipulating co-stimulatory signals, enhancing antigen presenting cell activity, and using cytokines to augment anti-tumor immune responses.
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
This document discusses various cancer immunotherapy approaches for treating high grade glial tumors, including tumor immunotherapy using exogenously produced and reinfused cytotoxic T cells, depletion of immunosuppressive Treg cells, genetic production and propagation of T cells carrying tumor-antigen specific T cell receptors, vaccination approaches using peptide vaccines, dendritic cell vaccines, and autologous/whole tumor cell vaccines. It also discusses the advantages and disadvantages of different vaccine types as well as ways to augment antitumor immunity, including through adoptive T cell therapy, checkpoint inhibitors, cytokines, and other agents.
Tumor immunity
This document discusses tumor immunity and immunotherapy approaches for cancer. It covers:
- Tumor antigens that can be recognized by the immune system, including tumor-specific antigens from mutations and tumor-associated antigens normally expressed.
- Components of the innate and adaptive immune response against tumors, like T cells, macrophages, and cytokines.
- Mechanisms of "tumor escape" from immune recognition like downregulating MHC proteins.
- Immunotherapy approaches including vaccines targeting tumor antigens, immune modulation using cytokines or other agents, oncolytic viruses, and passive transfer of immune cells like antibodies or T cells.
Tumour immunology
The document discusses cancer immunosurveillance and immunoediting. It describes how the immune system plays an important role in controlling cancer development through 3 phases - elimination, equilibrium, and escape. In the elimination phase, innate and adaptive immunity work to eliminate cancer cells. Some cancer cells may survive this phase if they acquire properties to evade the immune system, entering the equilibrium phase. Eventually, in the escape phase, cancer cells are able to avoid immune destruction through various mechanisms and form clinically detectable tumors. Immunotherapy aims to enhance the immune response against cancer cells.
Advanced tumor immunology prof dr.ihsan edan alsaimary university of basrah...
This document discusses various topics related to tumors and cancer, including:
1. The properties of cancer cells such as being clonally derived, having altered growth patterns, tissue affinities, and chromosomal abnormalities.
2. The development of tumor antigens, including tumor specific antigens from mutations and viral proteins, as well as tumor associated antigens like oncofetal antigens.
3. The process of metastasis, where tumor cells spread via direct seeding, lymphatics, or hematogenous routes, requiring changes in adhesion molecules, proteolytic enzymes and growth factors.
4. Common tumor markers used to screen and monitor cancers, including CEA, CA-125, PSA, and AFP
cancer de mama
This document discusses cancer immunology and the immune system's response to cancer. It covers topics like tumor antigens, cells of the immune system like T cells, B cells, and antigen-presenting cells. It also summarizes theories of cancer immunoediting where the immune system eliminates, edits, or reaches an equilibrium with tumors. The document outlines mechanisms tumors use to escape immune destruction like expressing inhibitory molecules. It concludes by discussing immunotherapies to modulate the immune response and target cancers.
Immunobiology of cancer
This document summarizes the immunobiology of cancer. It discusses how the innate and adaptive immune system provides immunosurveillance against cancer through mechanisms like immunosurveillance and immunoediting. However, cancer cells can evade the immune system through various mechanisms. Hepatocellular carcinoma is discussed as an example where the immune response against it can fail through different cell types and pathways. Immunotherapy is presented as a way to take advantage of the immune response against cancer through passive and active approaches.
Mucinous adenocarcinoma-of-the-colon-mimicking-an-abdominal-wall-cellulitis
Introduction
Cutaneous metastases from abdominal malignancies are rare and have been reported in less than 5% of patients [1]. Furthermore, metastases in patients suffering from colorectal neoplasia are even rarer entity. Tan et al, among 2538 of the new cases of colorectal cancer over the period of 6 years, reported only 3 cases (0.1%) with cutaneous deposits [1]. Presentation varies from cutaneous or subcutaneous small nodules, rash or large fungating lesions [1-4]. Inevitably, their presence implies the disease progression, and poor prognosis with the reported survival between 1 to 34 months [2,3,5].
We report a case of an elderly patient who initially was thought to present with a simple skin infection. Subsequently, the patient was diagnosed with the moderately differentiated mucinous adenocarcinoma and required the right hemicolectomy. This case highlights that a high index of suspicion is recommended in an unresolving skin erythema.
1805 bio equity_podium v3
This document summarizes Targovax's approach to activating the immune system to fight cancer. It discusses moving from sequential treatment strategies like surgery, radiation, and chemotherapy to a combination approach harnessing the immune system. Targovax's focus is on immune activators like oncolytic viruses and vaccines to make cancer visible to the immune system. The document outlines Targovax's clinical programs using oncolytic viruses ONCOS and therapeutic cancer vaccine TG, including current and planned trials in cancers like mesothelioma, melanoma, and colorectal cancer. Early data from a phase I/II trial of ONCOS-102 in mesothelioma shows safety and signs of efficacy.
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
This document discusses granulopoiesis, neutrophils, and neutropenia. It defines neutropenia as an abnormally low level of neutrophils in the bloodstream. Severe neutropenia, when neutrophil counts drop below 500 cells/mm3, can lead to life-threatening infections. The document outlines risk factors for infections in neutropenic cancer patients and describes the evaluation and treatment of febrile neutropenia, including assessing patient risk level to determine treatment approach.
More Related Content
What's hot
Tumor immunology by nidhi
What is immunology?
What is Tumor?
Types of tumor
Classification of Malignant tumors
Malignant transformation of cells
General features of Tumor immunity
Tumor antigens
Tumor specific antigen
Tumor associated antigens
Immune response to tumor
Evasion of immune response by tumor
Cancer Immunosurveillance versus Immunoediting
Immunotechniques
RIA
ELISA
ppt 1
The document discusses tumor immunology and tumor markers. It provides information on:
1) How tumors form from normal cells through mutations, carcinogens or viruses and become antigenically different. The immune system normally recognizes and destroys these cells.
2) Mechanisms by which tumors can escape immune detection including loss of antigen presentation or production of immunosuppressive factors.
3) How the immune system acts as a surveillance system to detect and eliminate neoplastic cells through natural killer cells, cytotoxic T-cells, antibodies and complement activation.
4) Tumor markers that can be used for diagnosis and monitoring treatment including tumor antigens like alpha-fetoprotein and carcinoembryonic antigen, and tumor
Tumour immunology
The document discusses tumors and cancer. It defines tumors as abnormal tissue growth resulting from mutations in DNA that alter cell growth regulation. There are two types: benign tumors, which are non-cancerous and have defined boundaries; and malignant tumors (cancers), which invade other tissues and spread via the bloodstream and lymphatic system. Cancers arise from mutations in oncogenes and tumor suppressor genes, which normally regulate cell division. Environmental factors like radiation, viruses, hormones, and chemicals can also increase cancer risk by further mutating these genes. The body has some defense mechanisms to prevent cancer development, like shedding mutated cells, but cancers can still form when too many mutations accumulate.
Cancer and the Immune System
The presentation outlines aspects of immunity against cancer, evasion strategies by cells, immunotherapy in cancer, cancer vaccines etc. Download and view the slideshow for better experience.
Prepared in Sept 2014
Immune response against tumors
The document discusses various types of tumor antigens recognized by T cells and immune mechanisms of tumor rejection. It covers tumor-associated antigens and tumor-specific antigens, and describes four main categories of tumor antigens: 1) abnormally expressed but unmutated cellular proteins, 2) products of mutated self genes, 3) oncogenes and mutated tumor suppressor genes, and 4) antigens of oncogenic viruses. It also discusses how tumors can evade immune responses through mechanisms like antigen loss, inhibiting immune molecules, regulatory T cells, and secreting immunosuppressive factors. Novel immunotherapies discussed include therapeutic cancer vaccines, monoclonal antibodies, immune checkpoint inhibitors, adoptive cell therapies, and oncolytic viruses.
Cancer immunology
The document summarizes key concepts in cancer immunology. It defines cancer and how the immune system views cancer cells. It describes how the innate and adaptive immune systems recognize and attack tumors through mechanisms like complement activation, NK cell activation, and T cell responses. It also discusses how cancers can evade the immune system through antigen loss, immunosuppressive microenvironments, and immune checkpoint proteins. The document concludes by outlining several immunotherapy approaches like non-specific immune stimulation, T cell therapy, immune checkpoint inhibitors, cancer vaccines, and monoclonal antibodies.
Cancer and immune system
Cancer can both weaken the immune system and be fought by the immune system. It can weaken immunity by spreading to bone marrow and reducing blood cell production, or through side effects of treatments like chemotherapy and radiation. However, parts of the immune system also recognize cancer cells as abnormal and try to kill them. New immunotherapies aim to boost this response by using antibodies, cytokines, vaccines, and other methods to help the immune system better eliminate cancer cells. A balanced relationship exists between cancer and immunity.
CANCER IMMUNOLOGY- TERMINOLOGIES
Cancer immunology involves the immune system's response to tumors. There are several key terms: tumors can be benign (non-invasive) or malignant (invasive and metastatic). Malignant tumors are called cancers. Cancers arise from epithelial tissues, blood cells, or connective tissues. Chemicals, radiation, viruses and genetic mutations can cause malignant transformation of cells. Oncogenes promote tumor growth while tumor suppressors inhibit growth. Tumors express antigens that can be recognized by the immune system, including tumor-specific antigens from mutations and tumor-associated antigens that are normally expressed elsewhere.
Tumourclasss
1. A tumor is abnormal tissue consisting of genetic-altered cells that can arise due to mutations or environmental factors like radiation or infections.
2. The immune system can recognize and destroy early cancer cells but tumors evolve mechanisms to evade the immune response through loss of antigen presentation or secretion of factors that suppress T cells.
3. Immunotherapy aims to enhance anti-tumor immunity through vaccines, adoptive cell therapies, monoclonal antibodies, or cytokines to help the immune system overcome tumor evasion and eliminate cancer cells in a targeted manner with less toxicity than other treatments.
Tumor Immunology presentation by Sharmista
Tumor, Tumor immunology, cancer, hallmarks of cancer, carcinoma, lymphoma, metastasis, malignant, benign, angiogenesis, oncogenes and cancer induction, kuby detailed study quick revision, proto-oncogenes, tumor antigens, antibody, experiments for tumor antigens, methods for characterization of TSTA, Immunoediting, Current research n new approaches, monoclonal antibody
Cancer immunology
Tumor immunotherapy activates a patient's immune system to fight cancer. There are two main types of immunotherapy - antigen-specific therapies which directly transfer immune cells or induce immune responses to specific antigens, and non-specific therapies which stimulate immune function regardless of antigen specificity. Adoptive transfer directly transfers immune cells while vaccination administers antigens to induce immune responses. Non-specific therapies were once tested on their own but are now used alongside antigen-specific therapies to enhance communication between immune cells.
Theory of Immune surveillance
The document discusses the theory of immune surveillance, which proposes that the immune system patrols the body to recognize and destroy both invading pathogens and abnormal host cells, such as cancer cells. It provides evidence from experiments in mice and clinical observations in humans that support this theory. The key components of immune surveillance systems that eliminate cancer cells are natural killer cells, cytotoxic T-lymphocytes, B-cells, and their mechanisms of action. The process by which cancer cells can evade immune destruction is called immunoediting, which occurs through three sequential phases - elimination, equilibrium, and escape.
Cancer immunology
This document provides an overview of cancer immunology, including how tumors evade and enhance immune responses. It discusses the roles of various immune cells like NK cells, macrophages, and cytotoxic T lymphocytes in targeting tumor antigens. The document also covers cancer immunotherapy approaches like manipulating co-stimulatory signals, enhancing antigen presenting cell activity, and using cytokines to augment anti-tumor immune responses.
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
This document discusses various cancer immunotherapy approaches for treating high grade glial tumors, including tumor immunotherapy using exogenously produced and reinfused cytotoxic T cells, depletion of immunosuppressive Treg cells, genetic production and propagation of T cells carrying tumor-antigen specific T cell receptors, vaccination approaches using peptide vaccines, dendritic cell vaccines, and autologous/whole tumor cell vaccines. It also discusses the advantages and disadvantages of different vaccine types as well as ways to augment antitumor immunity, including through adoptive T cell therapy, checkpoint inhibitors, cytokines, and other agents.
Tumor immunity
This document discusses tumor immunity and immunotherapy approaches for cancer. It covers:
- Tumor antigens that can be recognized by the immune system, including tumor-specific antigens from mutations and tumor-associated antigens normally expressed.
- Components of the innate and adaptive immune response against tumors, like T cells, macrophages, and cytokines.
- Mechanisms of "tumor escape" from immune recognition like downregulating MHC proteins.
- Immunotherapy approaches including vaccines targeting tumor antigens, immune modulation using cytokines or other agents, oncolytic viruses, and passive transfer of immune cells like antibodies or T cells.
Tumour immunology
The document discusses cancer immunosurveillance and immunoediting. It describes how the immune system plays an important role in controlling cancer development through 3 phases - elimination, equilibrium, and escape. In the elimination phase, innate and adaptive immunity work to eliminate cancer cells. Some cancer cells may survive this phase if they acquire properties to evade the immune system, entering the equilibrium phase. Eventually, in the escape phase, cancer cells are able to avoid immune destruction through various mechanisms and form clinically detectable tumors. Immunotherapy aims to enhance the immune response against cancer cells.
Advanced tumor immunology prof dr.ihsan edan alsaimary university of basrah...
This document discusses various topics related to tumors and cancer, including:
1. The properties of cancer cells such as being clonally derived, having altered growth patterns, tissue affinities, and chromosomal abnormalities.
2. The development of tumor antigens, including tumor specific antigens from mutations and viral proteins, as well as tumor associated antigens like oncofetal antigens.
3. The process of metastasis, where tumor cells spread via direct seeding, lymphatics, or hematogenous routes, requiring changes in adhesion molecules, proteolytic enzymes and growth factors.
4. Common tumor markers used to screen and monitor cancers, including CEA, CA-125, PSA, and AFP
cancer de mama
This document discusses cancer immunology and the immune system's response to cancer. It covers topics like tumor antigens, cells of the immune system like T cells, B cells, and antigen-presenting cells. It also summarizes theories of cancer immunoediting where the immune system eliminates, edits, or reaches an equilibrium with tumors. The document outlines mechanisms tumors use to escape immune destruction like expressing inhibitory molecules. It concludes by discussing immunotherapies to modulate the immune response and target cancers.
Immunobiology of cancer
This document summarizes the immunobiology of cancer. It discusses how the innate and adaptive immune system provides immunosurveillance against cancer through mechanisms like immunosurveillance and immunoediting. However, cancer cells can evade the immune system through various mechanisms. Hepatocellular carcinoma is discussed as an example where the immune response against it can fail through different cell types and pathways. Immunotherapy is presented as a way to take advantage of the immune response against cancer through passive and active approaches.
What's hot (19)
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
Advanced tumor immunology prof dr.ihsan edan alsaimary university of basrah...
Advanced tumor immunology prof dr.ihsan edan alsaimary university of basrah...
Similar to Your immune system and cancer - Jonathan Cebon - BreaCan 5 August 2015
Mucinous adenocarcinoma-of-the-colon-mimicking-an-abdominal-wall-cellulitis
Introduction
Cutaneous metastases from abdominal malignancies are rare and have been reported in less than 5% of patients [1]. Furthermore, metastases in patients suffering from colorectal neoplasia are even rarer entity. Tan et al, among 2538 of the new cases of colorectal cancer over the period of 6 years, reported only 3 cases (0.1%) with cutaneous deposits [1]. Presentation varies from cutaneous or subcutaneous small nodules, rash or large fungating lesions [1-4]. Inevitably, their presence implies the disease progression, and poor prognosis with the reported survival between 1 to 34 months [2,3,5].
We report a case of an elderly patient who initially was thought to present with a simple skin infection. Subsequently, the patient was diagnosed with the moderately differentiated mucinous adenocarcinoma and required the right hemicolectomy. This case highlights that a high index of suspicion is recommended in an unresolving skin erythema.
1805 bio equity_podium v3
This document summarizes Targovax's approach to activating the immune system to fight cancer. It discusses moving from sequential treatment strategies like surgery, radiation, and chemotherapy to a combination approach harnessing the immune system. Targovax's focus is on immune activators like oncolytic viruses and vaccines to make cancer visible to the immune system. The document outlines Targovax's clinical programs using oncolytic viruses ONCOS and therapeutic cancer vaccine TG, including current and planned trials in cancers like mesothelioma, melanoma, and colorectal cancer. Early data from a phase I/II trial of ONCOS-102 in mesothelioma shows safety and signs of efficacy.
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
This document discusses granulopoiesis, neutrophils, and neutropenia. It defines neutropenia as an abnormally low level of neutrophils in the bloodstream. Severe neutropenia, when neutrophil counts drop below 500 cells/mm3, can lead to life-threatening infections. The document outlines risk factors for infections in neutropenic cancer patients and describes the evaluation and treatment of febrile neutropenia, including assessing patient risk level to determine treatment approach.
Cancer vaccine from mice to humans
This document summarizes the history and development of cancer vaccines from early experiments in mice to current human clinical trials. It discusses key concepts like antigen presentation and types of vaccine components. Murine studies showed synergistic effects of combining vaccines with checkpoint inhibitors. Human trials demonstrated the first FDA-approved therapeutic cancer vaccine Provenge for prostate cancer in 2010 and the oncolytic virus therapy T-VEC for melanoma in 2015. Data from the NCI Surgery Branch showed durable responses in some patients treated with personalized peptide vaccines.
180528 red eye_podium
This document discusses Targovax's focus on immune activators to treat cancer. It summarizes:
1) Targovax's approach of using oncolytic viruses and vaccines to activate T-cells to target tumors, rather than directly targeting cancer through surgery, radiation, or chemotherapy.
2) Targovax's two programs - ONCOS, an oncolytic virus, and TG, a therapeutic cancer vaccine - and their clinical development strategies.
3) Early positive results from a Phase I/II trial of ONCOS-102 for malignant pleural mesothelioma, with the drug showing safety, innate and adaptive immune activation, and early signs of clinical activity.
Immediate Management of Appendiceal Goblet Cell Carcinoid Initially Diagnosed...
A 42-year-old man presented with abdominal pain and was diagnosed with perforated appendicitis. He underwent a laparoscopic appendectomy which revealed a goblet cell carcinoid tumor. As the margins were positive, he had a laparoscopic right hemicolectomy. Pathology confirmed a 6.6cm goblet cell carcinoid with focal adenocarcinoma. While antibiotics may treat uncomplicated appendicitis, immediate surgery is needed to diagnose and treat alternative causes like carcinoid tumors to prevent recurrence and metastasis. Non-operative management risks missing timely diagnosis and treatment of appendiceal cancers.
Abdominal Pain as Initial Presentation of Lung Adenocarcinoma
Isolated celiac lymph node metastasis (ICLNM), in general, is not common with a reported incidence of 5–10% for lung adenocarcinoma. Lung adenocarcinoma rarely metastasizes to the celiac lymph node leading to abdominal pain. It is not typical for ICLNM to be the initial presentation of lung adenocarcinoma as well. In this case, a 56-year-old man presented with a 4-week history of persistent periumbilical dull pain. Workup was remarkable for celiac lymph node mass which turned out to be adenocarcinoma with unknown primary cancer. Whole body position emission tomography scan and biopsy of the mass with immunohistochemistry could identify lung adenocarcinoma as the primary cancer. After a well-informed discussion of options for chemotherapy drugs with the patient, the decision was made to pursue bevacizumab combined with chemotherapeutics. He was charged home with abdominal pain relief and outpatient follow-up after short-course of chemotherapy.
Merkel Cell Carcinoma: From Diagnosis to Treatment (webinar)
This document provides an overview of Merkel cell carcinoma, including its histogenesis, pathogenesis, epidemiology, clinical features, diagnosis, staging, treatment options for both localized and metastatic disease, and prognosis. Key points discussed are the role of Merkel cell polyomavirus in pathogenesis, increasing incidence with age and sun exposure, diagnosis through biopsy and immunohistochemistry, standard treatment involving surgery and/or radiation for localized disease and chemotherapy or immunotherapy for advanced stages, and generally poor prognosis especially for metastatic or recurrent disease.
Primary mediastinal liposarcoma of the superior, middle, and anterior mediast...
Primary mediastinal liposarcoma of the superior, middle, and anterior mediast...Mary Ondinee Manalo Igot
Primary mediastinal liposarcoma of the superior, middle, and anterior mediastinum
https://www.actamedicaphilippina.org/issue/1102immunotherapeutics History, Classification and Humanization Antibody Therapy....
This document provides a history of immunotherapy and describes current types of immunotherapy. It discusses early observations of tumour regression following infection in the 1800s which led to the first immunotherapy treatments using bacteria. Major developments include the discovery of tumour antigens in the 1940s-60s, approval of the first immunotherapy drug in 1986, and development of checkpoint inhibitors and CAR T-cell therapies in the 1990s-2010s. The document categorizes current immunotherapy types as adoptive cell therapies, cancer vaccines, immunomodulators, oncolytic virus therapy, targeted antibodies. It provides more detail on adoptive cell therapy approaches including TIL, TCR, CAR T-cell and NK cell therapies.
C-KIN formal presentation 2015
Detailed presentation of the Cancer & the Kidney International Network.
Partnership opportunities.
Developments in precision/personalized therapies: Robert Petit (Advaxis)
Developments in precision/personalized therapies: Robert Petit (Advaxis)Canadian Organization for Rare Disorders
Advaxis is developing a personalized neoepitope immunotherapy called ADXS-NEO to target mutations specific to a patient's cancer. Recent advances in genomics, immunotherapy, and cancer biology have enabled a new understanding of cancer as unique to each patient. ADXS-NEO uses DNA sequencing to identify tumor-specific mutations, engineers these neoepitopes into a bacterial vector, and administers this to activate the patient's immune system to target and eliminate the cancer. Advaxis has several clinical programs testing this approach across multiple cancer types with the goal of empowering each patient's immune system to fight their own unique form of cancer.Unit 4 Introduction to cancer.pptx
The document discusses cancer, including its definition, prevalence, risk factors, types, stages, and services available in Nepal. Some key points:
- Cancer is characterized by abnormal cell growth that can invade tissues and spread to other parts of the body. It is one of the leading causes of death worldwide.
- Major risk factors include tobacco use, chronic infections, alcohol consumption, dietary factors, obesity, radiation, and genetic predisposition.
- Common cancers in Nepal are cervical, lung, breast, oral, and stomach cancers. Cancer services have expanded in recent decades with four radiation therapy centers now available.
- Staging involves determining how much cancer is present and where, in order to select the most
G. Poste. The Next Era in Immuno-Oncology.
This document summarizes a presentation by Dr. George Poste on the next era of immuno-oncology. It discusses cancer as a complex adaptive system and the challenges of tumor heterogeneity and resistance. It outlines passive immunotherapies like antibodies and cell therapies, as well as active immunotherapies like checkpoint inhibitors and vaccines. Combination immunotherapies aim to overcome limitations of single agents. Challenges include toxicity, biomarkers, and the complex interactions between the immune system and tumor microenvironment. Next generation immunotherapies seek better responses, durability, tolerability through new targets and combination approaches.
Surgical Mamnagent Of Cancer
This document discusses the role of surgery in cancer management. It covers how surgery is used for prevention, diagnosis, staging, treatment and palliation of cancer. Surgery has evolved from being the only treatment to one component of a multidisciplinary approach. It addresses the historical development of surgical oncology and examples of current and potential future surgical techniques for cancer.
Adenocarcinoma of Rectum with Scalp Nodules: A Rare Case Report and Review of...
1) A 55-year-old female presented with scalp nodules and rectal bleeding for 2 months. Biopsies confirmed adenocarcinoma in the rectum and scalp nodules.
2) After 5 cycles of chemotherapy with capecitabine and oxaliplatin, the patient's symptoms improved and the scalp lesions responded well.
3) Skin metastases from an internal malignancy usually indicate advanced disease and carry a poor prognosis, though this case was treated successfully with chemotherapy.
LUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGS
The document provides information on lung cancer management in low resource settings. It discusses limited resources for setup, equipment, manpower, money and management. It also discusses potential sources of support including government, NGOs, donations and volunteers. Statistics on lung cancer prevalence and mortality are presented. The epidemiology, risk factors, diagnosis, staging and treatment of lung cancer are summarized.
Controversies in diverticular disease and diverticulitis conference presentation
Controversies in diverticular disease and diverticulitis conference presentationDr Edward Fitzgerald
This document discusses several controversies and areas of ongoing debate in the treatment of diverticular disease. It summarizes recent evidence questioning traditional practices like routine antibiotics for uncomplicated diverticulitis, prophylactic resection after a single attack, and the natural history assumptions of disease progression. The role of laparoscopic versus open surgery and conservative management of complicated diverticulitis are also addressed. Overall, the treatment paradigm is shifting to a more conservative approach with many prior standards now being re-examined based on emerging evidence.Introduction to cancer vaccines
This intro is geared towards interested novices who wish to find a resource that can serve as a starting point for further self-study. This is not meant to replace a doctor's advice. Please approach a medical professional for any health condition.
Cervical cancer
The document discusses cervical cancer, including its epidemiology, risk factors, pathogenesis, clinical presentation, investigations, complications, treatment, and prevention. Cervical cancer is caused by human papillomavirus (HPV) and is the most common gynecologic cancer in women globally. Screening through Pap smear testing and HPV DNA testing can detect pre-cancerous lesions early and reduce cervical cancer incidence and mortality rates. Prevention involves HPV vaccination, screening programs, and sexual health education and advocacy.
Similar to Your immune system and cancer - Jonathan Cebon - BreaCan 5 August 2015 (20)
Mucinous adenocarcinoma-of-the-colon-mimicking-an-abdominal-wall-cellulitis
Mucinous adenocarcinoma-of-the-colon-mimicking-an-abdominal-wall-cellulitis
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
Immediate Management of Appendiceal Goblet Cell Carcinoid Initially Diagnosed...
Immediate Management of Appendiceal Goblet Cell Carcinoid Initially Diagnosed...
Abdominal Pain as Initial Presentation of Lung Adenocarcinoma
Abdominal Pain as Initial Presentation of Lung Adenocarcinoma
Merkel Cell Carcinoma: From Diagnosis to Treatment (webinar)
Merkel Cell Carcinoma: From Diagnosis to Treatment (webinar)
Primary mediastinal liposarcoma of the superior, middle, and anterior mediast...
Primary mediastinal liposarcoma of the superior, middle, and anterior mediast...
immunotherapeutics History, Classification and Humanization Antibody Therapy....
immunotherapeutics History, Classification and Humanization Antibody Therapy....
Developments in precision/personalized therapies: Robert Petit (Advaxis)
Developments in precision/personalized therapies: Robert Petit (Advaxis)
Adenocarcinoma of Rectum with Scalp Nodules: A Rare Case Report and Review of...
Adenocarcinoma of Rectum with Scalp Nodules: A Rare Case Report and Review of...
Controversies in diverticular disease and diverticulitis conference presentation
Controversies in diverticular disease and diverticulitis conference presentation
Recently uploaded
Adhd Medication Shortage Uk - trinexpharmacy.com
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
This quiz was conducted as a promotional event for the 2024 Annual Meet of Kerala Chapter of API.
More than 20 participants took part everyday !
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
Dr. ZANAB FARHEEN FAYAZ ,MDS(ORTHODONTICS & DENTOFACIAL ORTHOPEDICS ).
Ketone bodies and metabolism-biochemistry
This slide consists of all the topics of ketone . This can be used for exam purpose for writing about Diabetic keto acidosis etc . Thank you
Acute Gout Care & Urate Lowering Therapy .pdf
In this document , the management of acute gout attacks and a description of urate lowering therapy is mentioned.
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Kosmoderma Academy Of Aesthetic Medicine
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Do you have abnormal smell after periods? It may be vaginitis. Do not worry, herbal medicine Fuyan Pill can help you get a cure.
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Pharmacology of 5-hydroxytryptamine and Antagonist
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Fallopian tube blockage may cause female infertility. For treatment, herbal medicine Fuyan Pill can be a solution.
Recently uploaded (20)
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Your immune system and cancer - Jonathan Cebon - BreaCan 5 August 2015
- 1. Your Immunity System & Cancer Jonathan Cebon Austin Health, Olivia Newton-John Cancer Research Institute & Olivia Newton John Cancer & Wellness Centre
- 3. Cancer immunosurveillance theory 1967 Tumours can be recognized and eliminated by the immune system. Macfarlane Burnet (1899–1985).
- 4. Melanoma in donor renal graft - 16 years after initial resection Melanoma in donor renal graft - 16 years after initial resection MacKie NEJM. 2003
- 5. Case 1 Mrs R • Past: Crohn’s disease – In remission 1998 • Primary melanoma diagnosed – Abdominal wall, high risk, stage IIC June 99 • 1st recurrence: skin nodules July 99 • 2nd recurrence: Brain tumour – Treated with radiotherapy
- 6. August 1999 Admission to hospital with Crohn’s disease flare – Spontaneous regression of – Multiple subcutaneous metastases – 3cm liver metastasis Case 1 June 1999 Feb 2000
- 7. Case 1 May 2001 • 3rd melanoma recurrence: R proximal humerus – Resection + prosthesis May-Jun 2001 – Vitiligo gradually developed over face, trunk, arms Dec 2001 Gall bladder surgery pigmented masses No live melanoma Melanin-laden immune cells (macrophages)
- 8. Case 1 • Last clinical review Jun 2014 – Alive & well – No evidence of melanoma
- 9. Tumor infiltrating lymphocytes: association with improved survival Melanoma
- 10. Summary • Stage 4 melanoma: metastatic disease in brain, liver, bone, skin, mucosal surfaces • Median survival 7 months • Spontaneous remission associated with autoimmunity Crohn’s colitis • Discussion point: can autoimmunity be harnessed as a therapeutic tool?
- 11. Immune Checkpoint Blockade Ribas NEJM June 2012
- 12. T-cell receptor: Antigen-MHC CD28: B7 CTLA-4: B7
- 13. Feb 2014 June 2014 Melanoma in Liver Response to Yervoy
- 14. Immune Checkpoint Blockade Ribas NEJM June 2012
- 15. LUDWIG CANCER RESEARCH September 2013 April 2014 Anti-PD-1 Malignant Melanoma Pulmonary metastases 70y M
- 16. Combination anti-CTLA4 & anti-PD-1 Wolchok et al June 2013
- 17. Slide 18 Presented By Jedd Wolchok at 2013 ASCO Annual Meeting
- 18. Cancer Risk following Renal Transplant ANZ Dialysis & Transplant register 1997 8618 patients Cancer Number Risk Ratio CNS Lymphoma 17 >1000 Ureter 10 250 Parathyroid 2 200 Kaposi Sarcoma 18 86 Vulva/Vagina 40 43 Penis 7 24 Cervix 65 17 Bladder 54 7 Kidney 8 7 NH Lymphoma 83 7 Liver 8 6 Colon 50 2 Breast 42 1
- 19. PD-1 inhibitors Active in multiple cancer types (response rates reported at June 2015) • Melanoma (17-40%) • Lung (10-30%) • Kidney (12-29%) • Bladder (25%) • Ovarian (6-23%) • Head & Neck (14-20%) • Hodgkins Lymphoma (87%) • Gastric • Triple-ve breast • Mesothelioma • HCC • Cancers with mismatch repair gene defects
- 20. Summary & Conclusions • Cancer responds to immune attack • Understanding the underlying science has enabled effective new therapies to be developed • Clinical trials are underway to evaluate these treatments in many different cancer types